Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation
Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation
复制标题
DOI：
10.5582/bst.2016.01223
复制
发表时间：
2016-12-01
影响因子：
5.5
通讯作者：
Inomata, Yukihiro
中科院分区：
文献类型：
--
作者：
Oya, Yuki;Sugawara, Yasuhiko;Inomata, Yukihiro
肝移植后复发性丙型肝炎的管理仍然是一个挑战。在这里，我们报告了5例患者谁实现了病毒反应后，与ledipasvir和sofosbuvir联合治疗。所有患者均接受他克莫司治疗。在ledipasvir和sofosbuvir治疗之前没有进行剂量调整。所有患者都完成了预定的12周疗程，使用了全剂量的ledipasvir和sofosbuvir。没有大于2级的显著不良事件。在研究期间，未检测到急性排斥反应。他克莫司的谷浓度保持稳定。第12周时，在所有患者中均未检测到丙型肝炎病毒RNA。根据这项初步研究的结果，ledipasvir和sofosbuvir联合治疗12周对丙型肝炎病毒复发的活体肝移植受者有效且安全。
Management of recurrent hepatitis C following liver transplantation still remains a challenge. Here, we report five patients who achieved viral responses following combined treatment with ledipasvir and sofosbuvir. All the patients received tacrolimus for immunosuppression. No dose adjustment was made before the ledipasvir and sofosbuvir therapy. All completed the intended 12-week treatment course with the full dose of ledipasvir and sofosbuvir. There were no significant adverse events greater than grade 2. During the study period, no acute rejection episodes were detected. The trough levels of tacrolimus were maintained stably. Hepatitis C virus RNA was not detected at week 12 in any of the patients. Based on the findings from this pilot study, combined ledipasvir and sofosbuvir therapy for 12 weeks is effective and safe for living-donor liver transplantation recipients with recurrence of hepatitis C virus.